Genprex Inc (GNPX) concluded trading on Thursday at a closing price of $0.47, with 16.57 million shares of worth about $7.79 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -44.60% during that period and on February 13, 2025 the price saw a loss of about -1.01%. Currently the company’s common shares owned by public are about 8.51M shares, out of which, 8.27M shares are available for trading.
Stock saw a price change of -5.80% in past 5 days and over the past one month there was a price change of -36.18%. Year-to-date (YTD), GNPX shares are showing a performance of -44.69% which decreased to -90.39% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.28 but also hit the highest price of $5.41 during that period. The average intraday trading volume for Genprex Inc shares is 598.52K. The stock is currently trading -20.73% below its 20-day simple moving average (SMA20), while that difference is down -40.87% for SMA50 and it goes to -65.06% lower than SMA200.
Genprex Inc (NASDAQ: GNPX) currently have 8.51M outstanding shares and institutions hold larger chunk of about 3.92% of that.
The stock has a current market capitalization of $4.01M and its 3Y-monthly beta is at -0.20. It has posted earnings per share of -$11.92 in the same period. It has Quick Ratio of 0.86 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GNPX, volatility over the week remained 13.64% while standing at 10.95% over the month.
Stock’s fiscal year EPS is expected to rise by 81.16% while it is estimated to increase by 70.59% in next year. EPS is likely to grow at an annualized rate of 62.92% for next 5-years, compared to annual growth of 8.89% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by National Securities on January 26, 2021 offering a Buy rating for the stock and assigned a target price of $7 to it. Coverage by Noble Capital Markets stated Genprex Inc (GNPX) stock as an Outperform in their note to investors on April 29, 2019, suggesting a price target of $5 for the stock.
